BVNRY: AI 评分 50/100 — AI 分析 (4月 2026)

概要：

BVNRY是做什么的？

BVNRY的投资论点是什么？

BVNRY在哪个行业运营？

BVNRY有哪些增长机遇？

• MVA-BN RSV Vaccine: The MVA-BN RSV vaccine, currently in Phase III clinical trials, represents a significant growth opportunity for Bavarian Nordic. Respiratory syncytial virus (RSV) affects millions of people annually, particularly infants and the elderly, creating a substantial market for an effective vaccine. Successful completion of Phase III trials and subsequent regulatory approval could generate significant revenue streams, potentially reaching hundreds of millions of dollars annually, within the next 2-3 years. Bavarian Nordic's competitive advantage lies in its MVA-BN platform, which has demonstrated safety and efficacy in previous clinical trials.
• ABNCoV2 Vaccine: The ABNCoV2 vaccine, which has completed Phase II clinical trials for the treatment of SARS-CoV-2, offers a growth opportunity in the evolving market for COVID-19 vaccines. While the initial demand for COVID-19 vaccines has decreased, there remains a need for booster shots and vaccines that address emerging variants. If approved, ABNCoV2 could capture a share of this market, generating revenue in the tens of millions of dollars. The timeline for potential commercialization is dependent on further clinical trials and regulatory approvals, potentially within the next 1-2 years.
• TAEK-VAC Cancer Vaccine: The TAEK-VAC cancer vaccine, currently in Phase I/II clinical trials for the treatment of advanced HER2 and brachyury-expressing cancers, represents a long-term growth opportunity for Bavarian Nordic. The market for cancer vaccines is growing, driven by advances in immunotherapy and personalized medicine. Successful development and commercialization of TAEK-VAC could generate significant revenue, although the timeline is uncertain due to the early stage of clinical development. The potential market size could reach hundreds of millions of dollars annually, but commercialization is likely several years away.
• Geographic Expansion: Bavarian Nordic has the opportunity to expand its geographic presence, particularly in emerging markets where access to vaccines is limited. By partnering with local distributors and governments, the company can increase its sales and market share in these regions. This expansion could generate incremental revenue growth of 5-10% annually over the next 3-5 years. The company's existing infrastructure and expertise in vaccine development and manufacturing provide a competitive advantage in entering new markets.
• Government Contracts: Bavarian Nordic has a history of securing government contracts for its vaccines, particularly for smallpox and monkeypox. These contracts provide a stable revenue stream and support the company's research and development efforts. The company can continue to pursue government contracts for its existing vaccines and new vaccine candidates, ensuring a consistent source of funding and market access. The value of these contracts can range from tens to hundreds of millions of dollars annually, depending on the specific vaccine and the government's needs. Ongoing government preparedness initiatives for emerging infectious diseases will likely continue to drive demand.

• Market capitalization of $2.20 billion reflects investor confidence in Bavarian Nordic's vaccine portfolio and pipeline.
• P/E ratio of 10.51 suggests the company is undervalued compared to its earnings.
• Profit margin of 22.2% indicates strong profitability and efficient operations.
• Gross margin of 48.5% demonstrates the company's ability to maintain competitive pricing and manage production costs.
• The company's diverse vaccine portfolio, including smallpox, monkeypox, rabies, tick-borne encephalitis, and Ebola vaccines, provides multiple revenue streams and reduces reliance on a single product.

BVNRY提供哪些产品和服务？

• Develops and manufactures vaccines for infectious diseases.
• Commercializes vaccines for smallpox and monkeypox under the names IMVAMUNE, IMVANEX, and JYNNEOS.
• Offers rabies vaccine for human use under the name Rabipur/RabAvert.
• Provides tick-borne encephalitis vaccine under the name Encepur.
• Manufactures Ebola vaccine under the name MVABEA.
• Conducts clinical trials for vaccines targeting respiratory syncytial virus (RSV), SARS-CoV-2, and certain cancers.
• Partners with organizations like the National Cancer Institute and Public Health Service for research and development.

BVNRY如何赚钱？

• Develops and manufactures vaccines.
• Sells vaccines to governments and healthcare providers.
• Generates revenue through commercial sales of approved vaccines.
• Receives funding through government contracts and grants.
• Out-licenses vaccine technology and collaborates with other companies.

• Governments: Purchase vaccines for national stockpiles and public health programs.
• Healthcare Providers: Administer vaccines to patients in hospitals and clinics.
• International Organizations: Procure vaccines for global health initiatives.
• Military Organizations: Acquire vaccines to protect personnel from infectious diseases.

• Proprietary Vaccine Technology: Bavarian Nordic's MVA-BN platform provides a competitive advantage in developing safe and effective vaccines.
• Regulatory Expertise: The company has a strong track record of obtaining regulatory approvals for its vaccines.
• Government Relationships: Bavarian Nordic has established relationships with governments and public health organizations.
• Manufacturing Capabilities: The company has specialized manufacturing facilities for vaccine production.

什么因素可能推动BVNRY股价上涨？

• Upcoming: Phase III clinical trial results for MVA-BN RSV vaccine expected in late 2026.
• Ongoing: Government contracts for smallpox and monkeypox vaccines provide a stable revenue stream.
• Ongoing: Development of new vaccines for emerging infectious diseases.
• Upcoming: Potential regulatory approvals for ABNCoV2 vaccine for SARS-CoV-2 in 2027.
• Ongoing: Expansion into new geographic markets.

BVNRY的主要风险是什么？

• Potential: Clinical trial failures could negatively impact the company's pipeline and future revenue.
• Potential: Regulatory delays or rejections could delay the commercialization of new vaccines.
• Ongoing: Competition from larger pharmaceutical companies could erode market share.
• Potential: Changes in government funding priorities could reduce revenue from government contracts.
• Ongoing: Currency fluctuations could impact the value of the company's international sales.

BVNRY的核心优势是什么？

• Established portfolio of approved vaccines.
• Proprietary MVA-BN vaccine platform.
• Strong relationships with governments and public health organizations.
• Experienced management team.

BVNRY的劣势是什么？

• Reliance on government contracts for revenue.
• Competition from larger pharmaceutical companies.
• Dependence on successful clinical trial outcomes.
• Limited geographic presence in some markets.

BVNRY有哪些机遇？

• Expansion into emerging markets.
• Development of new vaccines for unmet medical needs.
• Strategic partnerships and collaborations.
• Increased government funding for vaccine research and development.

BVNRY面临哪些威胁？

• Clinical trial failures.
• Regulatory delays or rejections.
• Competition from new vaccine technologies.
• Changes in government funding priorities.

BVNRY的竞争对手是谁？

• Almirall SA — Focuses on dermatology and aesthetics. — (ALFRY)
• BioNTech SE — Specializes in mRNA-based vaccines and therapies. — (BRCTF)
• Genmab A/S — Develops antibody therapeutics for cancer. — (GENSF)
• Grifols SA — Produces plasma-derived therapies. — (GLPGF)
• Haw Par Corp — Diversified company with healthcare segment. — (HAWPF)

Key Metrics

• MoonshotScore: 50/100

Company Profile

• CEO: Paul John Chaplin
• Headquarters: Hellerup, DK
• Employees: 1,645
• Founded: 2013

AI Insight

• ADR Level: 1
• ADR Ratio: 1:1
• Home Market Ticker: BVNR

• OTC Tier: OTC Other
• Disclosure Status: Unknown